Market Overview

Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside'

Related PCYC
Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation
JMP Sees A 'Negative Market Tone' In Biotechnology
Related JNJ
Facebook, Google Make Glassdoor's List Of Top 50 Places To Work
Karyopharm Therapeutics' Top Execs Talk Recent Results In Multiple Myeloma And Acute Myeloid Leukemia
Dividend Growth - Size Matters ... A Lot! (Seeking Alpha)

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas downgraded Pharmacyclics Inc. (NASDAQ: PCYC) to Hold, while raising the price target from $205 to $235. The downgrade followed a Bloomberg report mentioning that Johnson & Johnson (NYSE: JNJ) and Novartis AG (NYSE: NVS) may be interested in acquiring the company for about $15 billion.

In the report, Deutsche Bank noted, "From our current TP of $205 we get to $226/sh by reducing the discount rate to 8% (from 8.5%) and reducing the tax rate to 20% (JnJ's current assumed tax rate). A 15% tax rate adds am add; $13/sh to the DCF (or $239/sh)."

"Every addl $1 billion in sales adds $30-35/sh to the DCF, we see a large co like JNJ or Novartis as potentially expanding the mkt beyond what we model," Karnauskas explained.

"Each 10% improvement in SG&A adds $2/sh to the DCF. We don't think that an acquirer can cut expenses much because the co is expected to have a good margin profile in our model," the analyst added.

"Using our range of $226/261/sh take out value could be $17.6-$20.4B," Karnauskas said, while adding that the hike in TP and downgrade in rating was "because we do not see much upside from current valuation at $221/sh."

Latest Ratings for PCYC

Mar 2015NomuraDowngradesBuyNeutral
Mar 2015Leerink SwannDowngradesOutperformMarket Perform
Mar 2015BTIG ResearchDowngradesBuyNeutral

View More Analyst Ratings for PCYC
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Downgrades Price Target Analyst Ratings


Related Articles (JNJ + NVS)

View Comments and Join the Discussion!